This concern is particularly relevant for individuals with pre-existing insulin resistance or those using the peptide long-term without breaks
Responses far beyond what either compound produces alone
Common (5-15% of users): Mild injection site reactions, minor digestive changes Uncommon (1-5%): Sleep changes, temporary fatigue, mild headache Rare (under 1%): Dizziness, flushing, mood changes Very Rare: Serious adverse effects rarely reported in community use Theoretical Concerns BPC-157s ability to stimulate angiogenesis (blood vessel formation) raises theoretical questions about its use in individuals with active cancer or high cancer risk
This allows the product to be supplied in multi-dose vials and used for repeated withdrawals, in contrast to preservative-free sterile water which is intended for single use only
It appears to modulate neurotransmitter systems, including dopamine and serotonin, and has shown efficacy in counteracting damage induced by various neurotoxins, suggesting potential applications in neurological conditions like Parkinson's disease and schizophrenia-like models
AOD-9604 plus metabolic peptides Combining AOD-9604 with other metabolic peptides requires more careful consideration